Inhibition of bone turnover by milk intake in postmenopausal women

被引:44
作者
Bonjour, Jean-Philippe [1 ]
Brandolini-Bunlon, Marion [2 ]
Boirie, Yves [2 ]
Morel-Laporte, Francoise [2 ]
Braesco, Veronique [2 ]
Bertiere, Marie-Claude [3 ]
Souberbielle, Jean-Claude [4 ]
机构
[1] Univ Hosp, Serv Bone Dis, CH-1211 Geneva, Switzerland
[2] Ctr Rech Nutr Humaine Auvergne, F-63009 Clermont Ferrand, France
[3] Ctr Rech & Informat Nutr, F-75314 Paris, France
[4] Hop Necker Enfants Malad, Lab Explorat Fonct, F-75015 Paris, France
关键词
Menopause; Milk supplementation; Calcium intake; Bone turnover;
D O I
10.1017/S0007114508937429
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 [营养与食品卫生学];
摘要
Increased postmenopausal bone turnover leads to bone loss and fragility fracture risk. In the absence of osteoporosis, risk preventive measures, particularly those modifying nutritional lifestyle, are appropriate. We tested the hypothesis that milk supplementation affects bone turnover related to biochemical markers in a direction that, in the long term, may he expected to reduce postmenopausal bone loss. Thirty healthy postmenopausal women aged 59.3 (SD 3.3) years were enrolled in a prospective crossover trial of 16 weeks. After a 4-week period of adaptation with diet providing 600 mg calcium plus 300 mg ingested as 250 ml semi-skimmed milk, participants were maintained during 6 weeks under the same 600 mg calcium diet and randomized to receive either 500 ml semi-skimmed milk, thus providing a total of 1200 mg calcium, or no milk supplement. In the next 6 weeks they were switched to the alternative regimen. At the end of the each period, i.e. after 4, 10 and 16 weeks, blood and urinary samples were collected. The changes in blood variables between the periods of 6 weeks without and with milk supplementation were: for parathyroid hormone, -3.2 pg/ml (P=0.0054); for crosslinked telopeptide of type I collagen, - 624 pg/ml (P < 0.0001); for propeptide of type I procollagen, -5.5 ng/ml (P=0.0092); for osteocalcin, -2.8 ng/ml (P=0.0014). In conclusion, a 6-week period of milk supplementation induced a decrease in several biochemical variables compatible with diminished bone turnover mediated by reduction in parathyroid hormone secretion. This nutritional approach to postmenopausal alteration in bone metabolism may be a valuable measure in the primary prevention of osteoporosis.
引用
收藏
页码:866 / 874
页数:9
相关论文
共 66 条
[1]
[Anonymous], 2005, NIH Consens State Sci Statements, V22, P1
[2]
A controlled trial of the effect of milk basic protein (MBP) supplementation on bone metabolism in healthy menopausal women [J].
Aoe, S ;
Koyama, T ;
Toba, Y ;
Itabashi, A ;
Takada, Y .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (12) :2123-2128
[3]
BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936
[4]
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial [J].
Bauer, DC ;
Black, DM ;
Garnero, P ;
Hochberg, M ;
Ott, S ;
Orloff, J ;
Thompson, DE ;
Ewing, SK ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1250-1258
[6]
BONE AND RENAL COMPONENTS IN HYPERCALCEMIA OF MALIGNANCY AND RESPONSES TO A SINGLE INFUSION OF CLODRONATE [J].
BONJOUR, JP ;
PHILIPPE, J ;
GUELPA, G ;
BISETTI, A ;
RIZZOLI, R ;
JUNG, A ;
ROSINI, S ;
KANIS, JA .
BONE, 1988, 9 (03) :123-130
[7]
Protein intake, IGF-1 and osteoporosis [J].
Bonjour, JP ;
Schurch, MA ;
Chevalley, T ;
Ammann, P ;
Rizzoli, R .
OSTEOPOROSIS INTERNATIONAL, 1997, 7 (Suppl 3) :36-42
[8]
The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report [J].
Boonen, S ;
Rizzoli, R ;
Meunier, PJ ;
Stone, M ;
Nuki, G ;
Syversen, U ;
Lehtonen-Veromaa, M ;
Lips, P ;
Johnell, O ;
Reginster, JY .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (07) :511-519
[9]
Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: A review of the evidence [J].
Boonen, S ;
Bischoff-Ferrari, HA ;
Cooper, C ;
Lips, P ;
Ljunggren, O ;
Meunier, PJ ;
Reginster, JY .
CALCIFIED TISSUE INTERNATIONAL, 2006, 78 (05) :257-270
[10]
At what hip fracture risk is it cost-effective to treat?: International intervention thresholds for the treatment of osteoporosis [J].
Borgstroem, F. ;
Johnell, O. ;
Kanis, J. A. ;
Joensson, B. ;
Rehnberg, C. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (10) :1459-1471